Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis. 2024

Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
A Giampietro, Pituitary Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, 00168, Italy.

OBJECTIVE Aim of this study was to examine the probability of achieving acromegaly disease control according to several patient-, disease- and treatment-related factors longitudinally. METHODS We analyzed data from ACROSTUDY, an open-label, non-interventional, post-marketing safety surveillance study conducted in 15 countries. 1546 patients with acromegaly and treated with pegvisomant, with available information on baseline IGF-1 level, were included. Factors influencing IGF-1 control were assessed up to 10 years of follow-up by mixed effects logistic regression models, keeping into account changing values of covariates at baseline and at yearly visits. Twenty-eight anthropometric, clinical, and treatment-related covariates were examined through univariate and multivariate analyses. We tested whether the probability of non-control was different than 0.50 (50%) by computing effect sizes (ES) and the corresponding 95% confidence intervals (CI). RESULTS Univariate analysis showed that age <40 years, normal or overweight, baseline IGF-1<300 ug/L or ranged between 300 and 500ug/L, and all pegvisomant dose <20mg/day were associated with a lower probability of acromegaly uncontrol. Consistently, in multivariate analyses, the probability of uncontrolled acromegaly was influenced by baseline IGF-1 value: patients with IGF-1<300 ug/L had the lowest risk of not-controlled acromegaly (ES=0.29, 95%CI:0.23-0.36). The probability of acromegaly uncontrol was also lower for values 300-<500ug/L (ES=0.37, 95%CI:0.32-0.43), while it was higher for baseline IGF-1 values ≥700ug/L (ES=0.58, 95%CI:0.53-0.64). CONCLUSIONS Baseline IGF-l levels were a good predictor factor for long-term acromegaly control. On the contrary, our data did not support a role of age, sex, BMI, and pegvisomant dose as predictors of long-term control of acromegaly.

UI MeSH Term Description Entries

Related Publications

Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
March 2020, European journal of endocrinology,
Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
March 2019, Endocrine,
Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
February 2017, European journal of endocrinology,
Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
November 2009, European journal of endocrinology,
Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
January 2021, Endocrine,
Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
December 2015, Annales d'endocrinologie,
Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
December 2018, European journal of endocrinology,
Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
January 2021, Endocrine,
Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
June 2022, Pituitary,
Antonella Giampietro, and Sabrina Chiloiro, and C Urbani, and Rosario Pivonello, and Martin Ove Carlsson, and Francesca Dassie, and Nunzia Prencipe, and Marta Ragonese, and Roy Gomez, and Simona Granato, and Salvatore Cannavò, and Silvia Grottoli, and Pietro Maffei, and Annamaria Colao, and Fausto Bogazzi, and Antonio Bianchi
October 2016, European journal of endocrinology,
Copied contents to your clipboard!